Effectiveness of Two Different Doses of BI 1026706 on the Overall Peak-to-Peak (PtP) N2/P2-component Amplitude of Laser (Somatosensory, Radiant-heat) Evoked Potentials (LEP) in UVB(Ultraviolet)-Irradiated Skin in Healthy Male Volunteers

• Status: Completed
• Trial end date: 2014-04-15

Summary

• To investigate the influence of different doses of BI 1026706 on the primary endpoint (PtP-amplitude LEP in UV skin) compared to placebo.

• The comparison of both doses of BI 1026706 to celecoxib in the UVB treatment.

• Comparison of both doses of BI 1026706 to placebo and pregabalin in the capsaicin treatment

• Exploration of the pharmacokinetics of BI 1026706

• Exploration of safety and tolerability of BI 1026706

• Phase: Phase 1

Details

• Lead Sponsor: Boehringer Ingelheim
• Treatments: Celecoxib; Pregabalin